Abstract
Hypertension awareness, treatment, and control rates have increased progressively over the past three decades. Data from the third National Health and Nutrition Examination Survey conducted from 1988–1991 indicate that the percentage of those aware of hypertension had increased to 73% (1). Of those aware, 55% were being treated, and 29% were controlled to a blood pressure of <140/90 mmHg. This information was considered in the preparation of the fifth report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) published in 1993 (2). Unfortunately, these awareness, treatment, and control rates have lessened since publication of the JNC V report (Table 1). Declines in age-adjusted mortality rates for stroke and coronary heart disease appear to be leveling in recent years (3). In fact, the age-adjusted stroke rate actually increased in the United States in 1993 for the first time in more than two decades. The incidence of end-stage renal disease (ESRD), for which high blood pressure is the second most common antecedent, continues to increase, as does the prevalence of congestive heart failure wherein the majority of patients also have antecedent hypertension (4,5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 [published erratum appears in Hypertension 1996 May;27(5):1192]. Hypertension 1995; 26: 60–69.
Joint National Committee. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 1993; 153: 154–183.
Data calculated for the National Heart, Lung, and Blood Institute staff, J. Cutler, Principal Investigator, January 1997.
United States Renal Data System 1997 Annual Data Report. Bethesda, MD: US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease.
Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562.
Joint National Committee. The sixth report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413–2446.
WHO Expert Committee on Hypertension Control. Hypertension Control: Report of a WHO Expert Committee. WHO Technical Report Series, no. 862, 1996, Geneva, Switzerland, World Health Organization.
National High Blood Pressure Education Program (NHBPEP) Working Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993; 153: 186–208.
Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–313.
The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, Phase II (TOHP II). Arch Intern Med 1997; 157: 657–667.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117–1124.
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739–745.
Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214–1218.
MacMahon S, Rodgers A. The effects of blood pressure reduction in older patients: An overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967–978.
Vasan RS. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996; 156: 1789–1796.
Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–1456.
Massie BM, Cleland JG, Armstrong PW, et al. Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. J Cardiac Fail 1998; 4: 3–8.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349–1355.
Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375–380.
Hjalmarson A, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994; 47 (Suppl 4): 31–39.
Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 1994; 92: 527–538.
van Zwieten PA. The rationale for the use of beta-blockers in the treatment of congestive heart failure. Am J Geriatr Cardiol 1992;(August):57–61.
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547–1552.
Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587–594.
Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.
Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997; 277: 1293–1298.
Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641–650.
National High Blood Pressure Education Program (NHBPEP) Working Group. 1995 Update of the Working Group Reports on Chronic Renal Failure and Renovascular Hypertension. Arch Intern Med 1996; 156: 1938–1947.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877–884.
Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939–945.
Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286–289.
American Diabetes Association. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 1997; 20 (Suppl 1): S1 - S70.
National High Blood Pressure Education Program (NHBPEP) Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145–158.
Curb JD, Pressel SL, Cutler JA, et al, for the Systolic Hypertension in the Elderly Program Cooperative Research Group. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886–1892.
Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction —evidence from clinical trials. N Engl J Med 1996; 335: 1660–1667.
Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–497.
National High Blood Pressure Education Program (NHBPEP) Working Group, Roccella EJ, Coordinator. National High Blood Pressure Education Program Working Group Report on hypertension in the elderly. Hypertension 1994; 23: 275–285.
Sagie A, Larson MG, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993; 329: 1912–1917.
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
Staessen J, Fagard R, Thijs LG, et al. Morbidity and mortality in the placebo-controlled European trial on isolated systolic hypertension in the elderly. Lancet 1997; 350: 757–764.
Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126: 761–767.
Materson BJ, Reda DJ, Cushman WC, et al. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men: A comparison of six anti-hypertensive agents with placebo [published correction appears in N Engl J Med 1994;330:1689]. N Engl J Med 1993; 328: 914–921.
Cruickshank JM, Thorpe JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet 1987; 1: 581–584.
Cooper SP, Hardy RJ, Labarthe DR, et al. The relation between degree of blood pressure reduction and mortality among hypertensives in the Hypertension Detection and Follow-Up Program. Am J Epidemiol 1988; 127: 387–403.
Waller PC, Isles CG, Lever AF, et al. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens 1988; 2: 7–10.
Fletcher AE, Beevers DG, Bulpitt CJ, et al. The relationship between a low treated blood pressure and IHD mortality: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hyper-tens 1988; 2: 11–15.
Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med 1992; 326: 251–254.
Medical Research Council Working Party. The MRC Mild Hypertension Trial: Some subgroup results. In: Strasser T, Gauten D, eds. Mild Hypertension: From Drug Trials to Practice. Raven Press, New York, 1987, pp. 9–20.
The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379–392.
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
Vidt DG, Pohl MA. Aggressive blood pressure lowering is safe, but benefit is still hard to prove. Cleve Clin J Med 1999; 66: 105–111.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vidt, D.G. (2001). Management of Hypertension. In: Foody, J.M. (eds) Preventive Cardiology. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-001-8_6
Download citation
DOI: https://doi.org/10.1007/978-1-59259-001-8_6
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-6241-9
Online ISBN: 978-1-59259-001-8
eBook Packages: Springer Book Archive